Literature DB >> 22318481

The role of intravascular ultrasound in the determination of progression and regression of coronary artery disease.

Hideaki Kaneda1, Mitsuyasu Terashima, Hiroshi Yamaguchi.   

Abstract

New imaging techniques have been used to examine surrogate markers of atherosclerotic burden to determine the effects of pharmacologic intervention. In this review, we discuss the role of intravascular ultrasound (IVUS) in the determination of progression and regression of coronary artery disease. Several methodologic issues are discussed (selection of segments to analyze, measurement error, high drop out rate, and optimal IVUS variables). Usefulness of new IVUS-derived variables (plaque composition by radiofrequency analysis, deformability by palpography, and endothelial shear stress by three-dimensional coronary anatomy reconstructed from IVUS and angiography) will be determined. Based on comparisons between IVUS and clinical studies, IVUS variables seem to be a valid surrogate in studies using atorvastatin in patients with dyslipidemia. It remains unclear whether IVUS variables are valid surrogates for other drugs/diseases. As such, further studies are needed to determine whether IVUS can serve as an efficient surrogate for clinical events in coronary disease trials.

Entities:  

Mesh：

Year:  2012        PMID： 22318481     DOI： 10.1007/s11883-012-0234-3

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  81 in total

1.  The accuracy of length measurements using different intravascular ultrasound motorized transducer pullback systems.

Authors:  Kaoru Tanaka; Stéphane G Carlier; Gary S Mintz; Koichi Sano; Xuebo Liu; Kenichi Fujii; Jose de Ribamar Costa; Joanna Lui; Jeffrey W Moses; Gregg W Stone; Martin B Leon
Journal:  Int J Cardiovasc Imaging       Date:  2007-03-17       Impact factor: 2.357

2.  Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.

Authors:  Jean-Claude Tardif; Jean Grégoire; Philippe L L'Allier; Reda Ibrahim; Todd J Anderson; François Reeves; Lawrence M Title; Erick Schampaert; Michel LeMay; Jacques Lespérance; Rob Scott; Marie-Claude Guertin; Marie-Luise Brennan; Stanley L Hazen; Olivier F Bertrand
Journal:  Atherosclerosis       Date:  2007-01-09       Impact factor: 5.162

3.  Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.

Authors:  Soon Jun Hong; Seung Cheol Choi; Chul Min Ahn; Jae Hyung Park; Jae Sang Kim; Do-Sun Lim
Journal:  Heart       Date:  2011-06-23       Impact factor: 5.994

4.  Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease.

Authors:  M Schartl; W Bocksch; D H Koschyk; W Voelker; K R Karsch; J Kreuzer; D Hausmann; S Beckmann; M Gross
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

5.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

6.  Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

Authors:  Jean-Claude Tardif; Jean Grégoire; Philippe L L'Allier; Reda Ibrahim; Jacques Lespérance; Therese M Heinonen; Simon Kouz; Colin Berry; Russell Basser; Marc-André Lavoie; Marie-Claude Guertin; Josep Rodés-Cabau
Journal:  JAMA       Date:  2007-03-26       Impact factor: 56.272

7.  Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.

Authors:  Takashi Nakayama; Nobuyuki Komiyama; Masaki Yokoyama; Susumu Namikawa; Nakabumi Kuroda; Yoshio Kobayashi; Issei Komuro
Journal:  Int J Cardiol       Date:  2008-09-24       Impact factor: 4.164

8.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

9.  Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries.

Authors:  Clemens von Birgelen; Marc Hartmann; Gary S Mintz; K Gert van Houwelingen; Nadine Deppermann; Axel Schmermund; Dirk Böse; Holger Eggebrecht; Till Neumann; Mario Gössl; Heinrich Wieneke; Raimund Erbel
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690

10.  Paradoxical arterial wall shrinkage may contribute to luminal narrowing of human atherosclerotic femoral arteries.

Authors:  G Pasterkamp; P J Wensing; M J Post; B Hillen; W P Mali; C Borst
Journal:  Circulation       Date:  1995-03-01       Impact factor: 29.690
View more
  2 in total

1.  Impact of spotty calcification on long-term prediction of future revascularization: a prospective three-vessel intravascular ultrasound study.

Authors:  Hiroto Tamaru; Kenichi Fujii; Masashi Fukunaga; Takahiro Imanaka; Kojiro Miki; Tetsuo Horimatsu; Machiko Nishimura; Ten Saita; Akinori Sumiyoshi; Masahiko Shibuya; Yoshiro Naito; Tohru Masuyama
Journal:  Heart Vessels       Date:  2015-05-12       Impact factor: 2.037

2.  Macrophages in Atherosclerosis Regression.

Authors:  Tessa J Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-11-14       Impact factor: 8.311
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.